Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study aims to see if a 12-week exercise program designed to reduce long periods of inactivity is feasible in newly diagnosed lymphoma participants receiving R-CHOP or POLA-R-CHP chemotherapy treatments, and whether it can improve heart health and reduce chemotherapy drug side effects.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Ability to understand and the willingness to sign informed consent prior to any study- related procedures.

• Patients diagnosed with lymphoma.

• Will receive first line R-CHOP or POLA-R-CHP chemotherapy regimens, patients do not need to be within a certain timeframe from diagnosis.

• Aged ≥18 years; due to the rarity of the disease in those \<18 years, this age bracket will not be included.

• Engaging in ≤60-minutes of structured moderate or vigorous intensity exercise.

• Have physician clearance to participate in exercise.

• Speak English.

• Willing to travel to Dana-Farber Cancer Institute for necessary data collection and exercise sessions.

• Access to a phone that can receive text messages.

Locations
United States
Massachusetts
Dana Farber Cancer Institute
RECRUITING
Boston
Contact Information
Primary
Christina Dieli-Conwright, MD, PhD
ChristinaM_Dieli-Conwright@dfci.harvard.edu
617-582-8321
Time Frame
Start Date: 2025-06-05
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 24
Treatments
Experimental: Interrupted Sedentary Time Intervention
The first 3 participants enrolled with be placed into the intervention group. After this, participants will be randomized in a group allocation ratio of 2:1 using permuted blocked design with varying block size and stratified by treatment plan. 14 participants will complete:~* Baseline visit~* Standard of care chemotherapy treatment regimen~* Daily exercise sessions in-clinic up to 4x weekly and at home 6 days per week~* Week 14 post-intervention visit
No_intervention: Usual Care Control Group
Participants will be randomized in a group allocation ratio of 2:1 using permuted blocked design with varying block size and stratified by treatment plan. 7 participants will complete:~* Baseline visit~* Standard of Care chemotherapy treatment regimen~* Week 14 visit~* Participants will be offered Fitbit activity tracker and resistance bands at the end of the study.
Related Therapeutic Areas
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Sponsors
Leads: Dana-Farber Cancer Institute

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

Enrollment Status: Recruiting
Publish Date: December 15, 2025
Intervention Type: Drug
Study Phase: Phase 3

Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)

Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)

Enrollment Status: Recruiting
Publish Date: April 01, 2021
Intervention Type: Other
Study Phase: Not Applicable

Phase I-II Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (R-DHAP) in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are Eligible for High Dose Treatment Followed by Autologous Stem Cell Transplantation

Phase I-II Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (R-DHAP) in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are Eligible for High Dose Treatment Followed by Autologous Stem Cell Transplantation

Who is this study for: Adult patients with diffuse large B-cell lymphoma
Enrollment Status: Recruiting
Publish Date: December 10, 2020
Intervention Type: Combination product, Drug
Study Drugs: R-DHAP, Brentuximab Vedotin
Study Phase: Phase 1/Phase 2
View All